GHRP-2

Growth Hormone Releasing Peptide-2

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as pralmorelin, is a synthetic hexapeptide that acts as a potent agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R). It triggers pulsatile growth hormone release from the pituitary gland, mimicking the body's natural GH secretion patterns. GHRP-2 was developed as a diagnostic agent and is clinically approved in Japan for assessing growth hormone deficiency. Unlike direct GH administration, GHRP-2 works through the body's natural pathways, making it a preferred option for those seeking to enhance their natural growth hormone production safely and effectively.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

•Increases insulin secretion (glucose-dependent)
•Suppresses glucagon release
•Slows gastric emptying
•Enhances satiety in hypothalamus
•Preserves beta-cell function

GIP Receptor Pathway

•Enhances insulin secretion (stronger than GLP-1)
•Promotes fat oxidation
•Improves insulin sensitivity in muscle
•Reduces hepatic glucose production
•Modulates adipose tissue metabolism

Why Dual Agonism is Superior

This peptide works through specific molecular pathways to achieve its therapeutic effects, with mechanisms tailored to its unique receptor targets and biological functions.

Pharmacokinetic Profile

~5 days

Half-life

8-72 hours

Tmax

80%

Bioavailability

99%

Protein binding

Proteolytic cleavage

Metabolism

Renal (primary)

Elimination

Peptide Database